Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) in Preventing Community-Acquired Pneumonia in Adults: A Population-Based Cohort Study

Overview

Journal Vaccines (Basel)

Date 2024 Sep 28

PMID 39340052

Authors

Mateu Serra-Prat

Ignasi Bolibar

Elisabet Palomera

Angel Lavado

Jordi Almirall

Affiliations

Soon will be listed here.

Abstract

Aim: The aim was to assess the effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) in preventing CAP in adults.

Methods: This was a population-based cohort study, followed up over 5 years (2015-2019), that included 47,768 persons aged ≥18 years assigned to three primary care centres. Data were retrospectively obtained from electronic medical records and databases. The vaccination effect was adjusted for potential confounders. Analyses were performed for the entire study population and for the ≥65 age subgroup.

Results: The annual incidence of CAP (per 10 adult inhabitants) was 3.29 overall, and 8.08 and 2.93 for vaccinated and non-vaccinated persons, respectively. The non-adjusted effect of PPV23 on CAP was evidenced by HR = 2.80 (95% CI: 2.32-3.37), and after adjusting for possible confounders, PPV23 showed no significant independent effect on CAP in the overall population (HR = 1.14; = 0.277) or in persons aged ≥65 years (HR = 1.30; = 0.051). No protective effect was observed in persons vaccinated <2 years previously (HR = 1.17; = 0.514).

Conclusions: PPV23 showed no effect in preventing CAP in adults aged ≥18 years or in the subgroup aged ≥65 years, even if vaccinated <2 years previously.

References

Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C . Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS One. 2017; 12(1):e0169368. PMC: 5218810. DOI: 10.1371/journal.pone.0169368. View

Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M . Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2005; 61(3):189-95. PMC: 2080738. DOI: 10.1136/thx.2005.043323. View

Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus F . Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk--A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(1):e0146338. PMC: 4711910. DOI: 10.1371/journal.pone.0146338. View

Kraicer-Melamed H, ODonnell S, Quach C . The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis. Vaccine. 2016; 34(13):1540-1550. DOI: 10.1016/j.vaccine.2016.02.024. View

Kim J, Chun B, Song J, Kim H, Bae I, Kim D . Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study. Vaccine. 2019; 37(21):2797-2804. DOI: 10.1016/j.vaccine.2019.04.017. View

Maruyama T, Taguchi O, Niederman M, Morser J, Kobayashi H, Kobayashi T . Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010; 340:c1004. PMC: 2834887. DOI: 10.1136/bmj.c1004. View

Diao W, Shen N, Yu P, Liu B, He B . Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials. Vaccine. 2016; 34(13):1496-1503. DOI: 10.1016/j.vaccine.2016.02.023. View

Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X . Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014; 58(7):909-17. DOI: 10.1093/cid/ciu002. View

Vila-Corcoles A, Hospital I, Ochoa-Gondar O, Satue E, de Diego C, Vila-Rovira A . Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016. Vaccine. 2019; 38(5):1170-1180. DOI: 10.1016/j.vaccine.2019.11.012. View

10.

Rozenbaum M, Pechlivanoglou P, van der Werf T, Lo-Ten-Foe J, Postma M, Hak E . The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2012; 32(3):305-16. DOI: 10.1007/s10096-012-1778-4. View

11.

Ardanuy C, Marimon J, Calatayud L, Gimenez M, Alonso M, Grau I . Epidemiology of invasive pneumococcal disease in older people in Spain (2007-2009): implications for future vaccination strategies. PLoS One. 2012; 7(8):e43619. PMC: 3425535. DOI: 10.1371/journal.pone.0043619. View

12.

Farrar J, Childs L, Ouattara M, Akhter F, Britton A, Pilishvili T . Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults. Pathogens. 2023; 12(5). PMC: 10222197. DOI: 10.3390/pathogens12050732. View

13.

Isturiz R, Grant L, Gray S, Alexander-Parrish R, Jiang Q, Jodar L . Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults. Clin Infect Dis. 2021; 73(7):1216-1222. PMC: 8492118. DOI: 10.1093/cid/ciab375. View

14.

Moberley S, Holden J, Tatham D, Andrews R . Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013; (1):CD000422. PMC: 7045867. DOI: 10.1002/14651858.CD000422.pub3. View

15.

Suzuki K, Kondo K, Washio M, Nakashima K, Kan S, Imai S . Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study. Hum Vaccin Immunother. 2019; 15(9):2171-2177. PMC: 6773389. DOI: 10.1080/21645515.2019.1584023. View

16.

Ferreira-Coimbra J, Sarda C, Rello J . Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. Adv Ther. 2020; 37(4):1302-1318. PMC: 7140754. DOI: 10.1007/s12325-020-01248-7. View

17.

Gonzalez-Romo F, Picazo J, Garcia Rojas A, Labrador Horrillo M, Barrios V, Magro M . [Consensus document on pneumococcal vaccination in adults at risk by age and underlying clinical conditions. 2017 Update]. Rev Esp Quimioter. 2017; 30(2):142-168. View

18.

Ochoa-Gondar O, Vila-Corcoles A, de Diego C, Satue E, Vila-Rovira A, Aragon M . [Antipneumococcal vaccination in Catalonian adults: Vaccine coverages and adequacy to distinct guideline recommendations]. Aten Primaria. 2018; 50(9):553-559. PMC: 6837116. DOI: 10.1016/j.aprim.2017.05.015. View

19.

Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A . Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine. 2009; 27(10):1504-10. DOI: 10.1016/j.vaccine.2009.01.013. View